Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2019

View Archived Issues

Taurolidine demonstrates efficacy in preclinical pediatric neuroblastoma studies

General protein synthesis inhibition in specific cells

Novel model of inflammatory enterocutaneous fistulas by transplantation of human fetal gut into mice

Phase I trial of nivolumab, alone or in combination, for unresectable/recurrent biliary tract cancer

Johnson & Johnson launches international research consortium to advance TB antibiotics

Patient enrollment ongoing in phase I/II study of DZD-9008 in NSCLC with EGFR or HER2 mutation

Positive phase III data presented from CHIASMA OPTIMAL study of Mycapssa

NLGN-1 as a potential new biomarker of synaptic loss in Alzheimer's disease

FGF-21 identified as a marker of islet function after transplantation

Roystonea regia lipid extract reduces lower urinary tract symptoms in men with BPH

Roche describes antibodies targeting vascular endothelial growth factor A

Sanford Burnham Prebys Medical Discovery Institute patents ACP1 inhibitors

TILRR is a new therapeutic target for treating vaginal HIV-1 infection

Indoleamine 2,3-dioxygenase 1 inhibitors identified at Bristol-Myers Squibb

Metallo-beta-lactamase inhibitors synthesized at Merck & Co.

Impetis Biosciences discovers adenosine A2A and/or A2B receptor antagonists

Activation of neuronal TRPV1 is sufficient to cause the equivalent of psoriasis

Novel pigenin derivative with anti-ischemic and neuroprotective effects following ischemia in rats

First results presented for reparixin in pancreatic islet transplantation in type 1 diabetes

Phase III OPTIMUM study of ponesimod in relapsing MS meets primary endpoint

Abeona announces interim data from phase I/II study of ABO-102 gene therapy for MPS IIIA

Aptevo advances clinical trials of APVO-210 and APVO-436

Researchers test nanochannel delivery implant for HIV drug cabotegravir

Seattle Genetics begins phase I trial of SGN-CD47M in advanced solid tumors

Inhibrx studies INBRX-101 in patients with alpha1-antitrypsin deficiency in new phase I trial